LinkedIn Profile

Access Theron Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:theronpharmaceuticals 9135241 Jun 4th, 2019 12:00AM Theron Pharmaceuticals, Inc. 26 2.00 Open Pharmaceuticals Jun 3rd, 2019 09:40PM Jun 3rd, 2019 09:40PM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Open 365 San Aleso Ave Sunnyvale California US 94085 Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Mar 23rd, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Mar 23rd, 2017 10:51AM Mar 23rd, 2017 10:51AM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 17th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 16th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 15th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 14th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 13th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 12th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 11th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology
private:theronpharmaceuticals 9135241 Feb 10th, 2018 12:00AM Theron Pharmaceuticals, Inc. 21 2.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products. Theron Pharmaceuticals Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.